Bl-M09D1
Gastrointestinal Tumor
Sichuan Baili Pharmaceutical Co., Ltd.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
43 Active assets in the Gastrointestinal Tumor cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Capecitabine China Medical University, China | Phase 3 | BB |
Sorafenib Sichuan Cancer Hospital and Research Institute | Phase 3 | BB |
Irinotecan Pfizer | Phase 3 | BB |
FLUOROURACILUM Janssen Research & Development, LLC | Phase 3 | BB |
Octreotide Pamoate Federico II University | Phase 2 | B |
View all 50 →
Same molecule, other indications
Bl-M09D1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →